Clinical trials: Triple Branch
Breast Cancer
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR positive breast cancer.
- Trial name
- NCT02833766
- Testing
- anti-EGFR-IL-dox
- Where
- 15 sites in Switzerland
- Volunteers
- 48 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative…
- Trial name
- NCT03546686
- Testing
- Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Texas Southwestern Medical Center
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
Breast Cancer Metastatic
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid…
- Trial name
- NCT06876636
- Testing
- Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Xijing Hospital
Triple-negative Breast Cancer
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
The goal of this clinical trial is to learn about the efficacy and safety of short-term sintilimab in combination with taxane and carboplatin for neoadjuvant therapy in female early-stage triple-negative breast caner patients…
- Trial name
- NeoSTEP (NCT05843292)
- Testing
- Taxane and Carboplatin, Short-term Sintilimab, Surgery
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
TNBC, Brain Metastasis
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases.
- Trial name
- NCT07623577
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Breast, Metastatic
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure…
- Conditions
- Breast, Metastatic, Triple Negative, Cancer
- Trial name
- EMPOWER (NCT04333706)
- Testing
- Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of Southern California
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
HIV
A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients
The purpose of this study is to evaluate the antiviral effect and durability of antiviral response (HIV-1 RNA PCR) and safety of a triple NtRTI/NsRTI therapy in antiretroviral naive patients.
- Trial name
- NCT00199121
- Testing
- Zidovudine (drug)
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Estrogen Receptor Negative, HER2/Neu Negative
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast cancer (breast cancer cells that do not have…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01964924
- Testing
- Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment…
- Trial name
- NCT06598046
- Testing
- Utidelone and capecitabine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
This is a phase II, open-labeled, multi-centered,single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) and eribulin mesylate in patients with…
- Trial name
- NCT04303741
- Testing
- Camrelizumab, Apatinib, Eribulin
- Where
- 3 sites in China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Cancer
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
- Trial name
- NCT05447702
- Testing
- Camrelizumab, Apatinib, Nab-paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- West China Hospital
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Magnetotherapy, Carpal Tunnel Syndrome (CTS)
Magnetotherapy in Carpal Tunnel Syndrome: Randomized Controlled Study
This study is designed to investigate the effectiveness of low-frequency pulsed electromagnetic field therapy in individuals diagnosed with mild-to-moderate carpal tunnel syndrome (CTS).
- Conditions
- Magnetotherapy, Carpal Tunnel Syndrome (CTS), Median Nerve Compression
- Trial name
- NCT07435961
- Testing
- Arm 1: Active Magnetotherapy Group, Arm 3: Conservative Treatment (Wait-List Control) Group
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Triple Negative Breast Cancer
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Trilaciclib is a highly potent, selective, and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy.
- Trial name
- NCT06955156
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- QIAO LI
Disorder Related to Renal Transplantation
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
Current practice of immune suppressive standard therapy after renal transplantation in non-risk patients is a triple therapy consisting of steroids, a calcineurin inhibitor and MMF.
- Trial name
- Harmony (NCT00724022)
- Testing
- Basiliximab, Tacrolimus, MMF, Prednisolon, Basiliximab, Tacrolimus, MMF, Tacrolimus, MMF, rATG
- Where
- 25 sites in Germany
- Volunteers
- 600 people
- Sponsor
- University Hospital Freiburg
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc